MCF Advisors’s Myriad Genetics MYGN Stock Holding History

MCF Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,011	Closed	-$33K	–	457
2021 Q3	$33K	Hold	1,011	–	–	﹤0.01%	353
2021 Q2	$31K	Hold	1,011	–	–	﹤0.01%	341
2021 Q1	$31K	Hold	1,011	–	–	﹤0.01%	321
2020 Q4	$20K	Hold	1,011	–	–	﹤0.01%	339
2020 Q3	$13K	Hold	1,011	–	–	﹤0.01%	362
2020 Q2	$11K	Sell	1,011 -3,775	-79%	-$53.6K	﹤0.01%	363
2020 Q1	$68K	Hold	4,786	–	–	0.01%	206
2019 Q4	$130K	Hold	4,786	–	–	0.02%	178
2019 Q3	$137K	Buy	4,786 +3,775	+373%	+$110K	0.02%	163
2019 Q2	$28K	Hold	1,011	–	–	﹤0.01%	286
2019 Q1	$34K	Hold	1,011	–	–	0.01%	259
2018 Q4	$29K	Sell	1,011 -5,000	-83%	-$180K	0.01%	259
2018 Q3	$277K	Buy	+6,011	New	+$267K	0.05%	102

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

MCF Advisors's MYGN Position: Q4 2021 in Review

MCF Advisors sold out of Myriad Genetics (MYGN) in Q4 2021, closing a stake of 1,011 shares — an estimated $33K sold.

MCF Advisors first reported a position in MYGN in Q3 2018 and held it in 13 quarters. The position peaked at $277K in Q3 2018. 197 funds tracked by Wall St. Rank hold MYGN as of Q4 2021.

MCF Advisors reported no remaining Myriad Genetics position as of Q4 2021 after selling out during the quarter.
MCF Advisors sold 1,011 Myriad Genetics shares in Q4 2021, an estimated $33K.
MCF Advisors first reported a position in Myriad Genetics in Q3 2018 and held it in 13 quarters.
MCF Advisors's Myriad Genetics position peaked at $277K in Q3 2018.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2021.

Based on MCF Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.